Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.42 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.42 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27856614 | 0.84 | ALDH1A1 (0.51) | KMT2AOPRK1HTTACHEALDH1A1 | |
| SCHEMBL3974935 | 0.84 | ACHE (0.52) | ACHEALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL29532414 | 0.84 | KMT2A (0.67) | KMT2AOPRK1HTTACHEALDH1A1 | |
| SCHEMBL2263219 | 0.84 | KMT2A (0.67) | KMT2AOPRK1HTTACHEALDH1A1 | |
| SCHEMBL11154554 | 0.81 | KMT2A (0.63) | KMT2AOPRK1HTTACHEALDH1A1 | |
| SCHEMBL28141574 | 0.81 | ACHE (0.50) | KMT2AOPRK1ACHEALDH1A1TDP1 | |
| SCHEMBL27961421 | 0.81 | KMT2A (0.63) | KMT2AOPRK1ACHEALDH1A1APEX1 | |
| SCHEMBL6505699 | 0.81 | KMT2A (0.63) | KMT2AOPRK1HTTACHEALDH1A1 | |
| SCHEMBL28133331 | 0.79 | KMT2A (0.60) | KMT2AOPRK1ACHEALDH1A1CYP3A4 | |
| SCHEMBL11706982 | 0.78 | KMT2A (1.00) | KMT2AOPRK1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107278201-A | Quinazoline derivatives for the treatment of HIV | 吉利德科学公司 | 2017-10-20 | — | — | CN | disclosed |
| US-6339089-B2 | ANTIHYPOXIC AGENTS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; VASOCONSTRICTION; REDUCES BLOOD PARTIAL PRESSURE OF CARBON DIOXIDE; RESPIRATORY DISORDERS; UNDER OXYGEN INHALATION TREATMENT | FUJIREBIO INC. (JP) | 2002-01-15 | — | — | US | disclosed |
| US-20010006969-A1 | PYRIMIDINE NUCLEUS-CONTAINING COMPOUND AND A MEDICAMENT CONTAINING THE SAME FOR A BLOOD OXYGEN PARTIAL PRESSURE AMELIORATION, AND A METHOD FOR PREPARING THE SAME | FUJIREBIO INC. (FUJIREBIO KABUSHIKI KAISHA) (JP) | 2001-07-05 | — | — | US | disclosed |
| EP-0899263-A2 | Fused pyrimidine derivatives and medicaments thereof for a blood oxygen partial pressure amelioration | Fujirebio Inc. (JP) | 1999-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010006969-A1 | PYRIMIDINE NUCLEUS-CONTAINING COMPOUND AND A MEDICAMENT CONTAINING THE SAME FOR A BLOOD OXYGEN PARTIAL PRESSURE AMELIORATION, AND A METHOD FOR PREPARING THE SAME | CYP11B2, CYP11B1, OAT | KMT2A 948/4885OPRK1 445/4885HTT 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.